glp-1 roche Weighs In With Encouraging Early Clinical Data for Oral Drug Carmot Therapeutics - Axial

Starting at $ 499 / Month GIP + GLP-1 receptor agonist that is FDA-approved for chronice weight management Zepbound Adults with obesity (BMI 30) or overweight (BMI 27 with a related health condition) Start TodayMore Info Potential Weight Loss* Administration methods** Injections Dose frequency*** Weekly Potential side effects Possible side effects may include nausea, vomiting, constipation, diarrhea, indigestion or stomach discomfort, reduced appetite, headache, fatigue, or injection site reactionsespecially when starting or increasing the dose

von Elm E, Altman DG, Egger M, Pocock SJ, Gtzsche PC, Vandenbroucke JP

This equation is commonly abbreviated as: C 1 V 1 = C 2 V 2

Adult study data In a head-to-head study in adults with type 2 diabetes, Victoza consistently outperformed Januvia 2 Primary endpoint: Mean change in A1C from baseline After 26 weeks Victoza vs Januvia vs Januvia Pratley (1860) Baseline A1C: 8.4% to 8.5% Studied in adults with type 2 diabetes taking metformin

Glp1r OBhM3Dq WD mice were administered 3 mg/kg CNO or an equivalent volume of saline at 9:00

BurgmaierMLibermanAMllmannJKahlesFReithSLebherzCet alGlucagon-like peptide-1 (GLP-1) and its split products GLP-1(937) and GLP-1(2837) stabilize atherosclerotic lesions in apoe(-)/(-) mice